Shenzhen Salubris Pharmaceuticals Co., Ltd.
002294
Kedudukan dalam Saham
#3418
Established in 1998 and headquartered in Shenzhen, China, Shenzhen Salubris... Established in 1998 and headquartered in Shenzhen, China, Shenzhen Salubris Pharmaceuticals Co., Ltd. operates across the entire pharmaceutical value chain, from research and development to manufacturing and sales. The company primarily focuses on critical therapeutic areas within China, including cardiovascular, anti-diabetic, anti-cancer, and orthopedic medicine. Its diverse product portfolio features a variety of cardiovascular and cerebrovascular medications, such as allisartan isoproxil and clopidogrel bisulfate tablets, alongside injectable options like bivalirudin. A significant offering is the recombinant SeV-hFGF2/dF Injection, specifically developed for the treatment of diabetic foot disease. Salubris also manufactures anti-tumor and orthopedic drugs. Furthermore, its anti-infective range encompasses numerous injectable antibiotics, including ceftazidime and ceftriaxone sodium, as well as oral preparations such as azithromycin dispersible and levetiracetam tablets. The firm also innovates in biotechnological drugs, developing recombinant proteins and monoclonal antibodies. Complementing its domestic operations, Shenzhen Salubris Pharmaceuticals engages in the import, in-licensing, and out-licensing of medicines, particularly for European markets.
Harga Saham
$4.48
Modal Pasaran
$4.99B
Perubahan (1 hari)
-5.20%
Perubahan (1 tahun)
-41.89%
Negara
CN
Perdagangan Shenzhen Salubris Pharmaceuticals Co., Ltd. (002294)
Kategori
Healthcare
Bilangan saham terbitan bagi Shenzhen Salubris Pharmaceuticals Co., Ltd. (002294)
Bilangan saham terbitan setakat June 2026: 1.11B
Menurut laporan kewangan terkini dan harga saham Shenzhen Salubris Pharmaceuticals Co., Ltd., bilangan saham terbitan semasa ialah 1.11B. Pada akhir December 2024, syarikat mempunyai 1.11B saham terbitan. Bilangan saham terbitan biasanya dipengaruhi oleh pecahan saham dan pembelian balik saham.
Sejarah saham terbitan untuk Shenzhen Salubris Pharmaceuticals Co., Ltd. (002294) dari 2006 hingga 2026
Saham terbitan pada akhir setiap tahun
| Tahun | Saham Terbitan | Ubah |
|---|---|---|
| 2026 (TTM) | 1.11B | -0.34% |
| 2025 | 1.11B | 0.07% |
| 2024 | 1.11B | -0.13% |
| 2023 | 1.12B | 1.55% |
| 2022 | 1.10B | 2.90% |
| 2021 | 1.07B | 3.79% |
| 2020 | 1.03B | -1.35% |
| 2019 | 1.04B | -0.33% |
| 2018 | 1.05B | 0.14% |
| 2017 | 1.04B | -0.14% |
| 2016 | 1.05B | 0.00% |
| 2015 | 1.05B | 0.36% |
| 2014 | 1.04B | -0.37% |
| 2013 | 1.05B | -0.14% |
| 2012 | 1.05B | 0.17% |
| 2011 | 1.05B | 0.15% |
| 2010 | 1.04B | 22.89% |
| 2009 | 849.71M | 8.80% |
| 2008 | 780.97M | -0.36% |
| 2007 | 783.76M | 19.22% |
| 2006 | 657.38M | 0.00% |
Saham terbitan bagi syarikat atau pesaing yang serupa
| Syarikat | Saham Terbitan | Perbezaan | Negara |
|---|---|---|---|
| 349.00M | -68.59% |
US
|
|
| 461.20M | -58.49% |
FR
|
|
| 334.63M | -69.88% |
JP
|
|
| 274.79M | -75.27% |
US
|
|
| - | - |
CH
|
